Efficacy of a Novel Method: VaSodilator Injection Via the Over-the-wire Lumen During Drug-coated Balloon Dilatation to Prevent the Slow-flow Phenomenon in Treatment of Femoropopliteal Lesions

Overview

Journal Heart Vessels

Specialty Cardiology & Vascular Diseases

Date 2024 Sep 24

PMID 39316099

Authors

Yuki Kozai

Shinsuke Mori

Masafumi Mizusawa

Shigemitsu Shirai

Yohsuke Honda

Masakazu Tsutsumi

Norihiro Kobayashi

Masahiro Yamawaki

Yoshiaki Ito

Affiliations

Soon will be listed here.

Abstract

In drug-coated balloon (DCB) angioplasty for femoropopliteal lesions, there are adverse effects of drug embolization on downstream non-target organs following the slow-flow phenomenon. We devised a novel method, known as VaSodilator injection via the Over-the-wire lumen during DCB dilatation to Prevent the slow-flow phenomenon in treatment of femoropopliteal lesions (V.S.O.P.), and evaluated its efficacy and safety. This single-center, retrospective, observational study analyzed 196 femoropopliteal lesions treated with IN.PACT Admiral between April 2018 and July 2023. The IN.PACT Admiral is a DCB consisting of a 0.035-inch over-the-wire (OTW) lumen balloon coated with high-dose paclitaxel. Regarding the V.S.O.P. method, we injected vasodilators through the OTW lumen during DCB dilation of the lesions. The cohort was classified into two groups according to the use of the V.S.O.P. method (V.S.O.P. group: n = 53; non-V.S.O.P. group: n = 143). The V.S.O.P. group had lower rates of hemodialysis (21% vs. 43%, p = 0.01) and higher rates of critical limb-threatening ischemia (56% vs. 23%, p < 0.01) and severe calcification lesions (Peripheral Arterial Calcium Scoring Systems score 3/4) (53% vs. 34%, p = 0.01) than the non-V.S.O.P. group. The occurrence of the slow-flow phenomenon was significantly lower in the V.S.O.P. group than in the non-V.S.O.P. group. The V.S.O.P. method could be an effective method for preventing the slow-flow phenomenon after DCB angioplasty for femoropopliteal lesions.

References

Soga Y, Takahara M, Iida O, Tomoi Y, Kawasaki D, Tanaka A . Vessel Patency and Associated Factors of Drug-Coated Balloon for Femoropopliteal Lesion. J Am Heart Assoc. 2022; 12(1):e025677. PMC: 9973589. DOI: 10.1161/JAHA.122.025677. View

Zeller T, Brodmann M, Ansel G, Scheinert D, Choi D, Tepe G . Paclitaxel-coated balloons for femoropopliteal peripheral arterial disease: final five-year results of the IN.PACT Global Study. EuroIntervention. 2022; 18(11):e940-e948. PMC: 9743239. DOI: 10.4244/EIJ-D-21-01098. View

Shimada T, Shima Y, Takahashi K, Miura K, Takamatsu M, Ikuta A . Delayed stenosis regression after drug-coated balloon angioplasty for femoropopliteal artery lesions. Heart Vessels. 2021; 37(5):730-737. DOI: 10.1007/s00380-021-01970-4. View

Kodama K, Soga Y, Tomoi Y, Sakai N, Imada K, Katsuki T . Difference in one-year late lumen loss between high- and low-dose paclitaxel-coated balloons for femoropopliteal disease. Heart Vessels. 2024; 39(7):582-588. PMC: 11189993. DOI: 10.1007/s00380-024-02370-0. View

Katsanos K, Spiliopoulos S, Teichgraber U, Kitrou P, Del Giudice C, Bjorkman P . Editor's Choice - Risk of Major Amputation Following Application of Paclitaxel Coated Balloons in the Lower Limb Arteries: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Eur J Vasc Endovasc Surg. 2021; 63(1):60-71. DOI: 10.1016/j.ejvs.2021.05.027. View

Thomas S, McDonald R, Varcoe R . Vasculitis resulting from a superficial femoral artery angioplasty with a paclitaxel-eluting balloon. J Vasc Surg. 2013; 59(2):520-3. DOI: 10.1016/j.jvs.2013.03.013. View

Torii S, Yahagi K, Mori H, Harari E, Romero M, Kolodgie F . Biologic Drug Effect and Particulate Embolization of Drug-Eluting Stents versus Drug-Coated Balloons in Healthy Swine Femoropopliteal Arteries. J Vasc Interv Radiol. 2018; 29(7):1041-1049.e3. DOI: 10.1016/j.jvir.2018.02.006. View

Torii S, Jinnouchi H, Sakamoto A, Romero M, Kolodgie F, Virmani R . Comparison of Biologic Effect and Particulate Embolization after Femoral Artery Treatment with Three Drug-Coated Balloons in Healthy Swine Model. J Vasc Interv Radiol. 2018; 30(1):103-109. DOI: 10.1016/j.jvir.2018.07.025. View

Tang T, Sulaiman M, Soon S, Yap C, Patel A, Chong T . Slow-flow phenomena following lower limb paclitaxel- and sirolimus-coated balloon angioplasty in the setting of chronic limb threatening ischaemia-a case series. Quant Imaging Med Surg. 2022; 12(3):2058-2065. PMC: 8899964. DOI: 10.21037/qims-21-633. View

10.

Shibata T, Iba Y, Nakajima T, Nakazawa J, Ohkawa A, Hosaka I . Initial Outcomes of Physician-Modified Inner Branched Endovascular Repair in High-Surgical-Risk Patients. J Endovasc Ther. 2023; 32(1):185-191. DOI: 10.1177/15266028231169183. View

11.

Farber A . Chronic Limb-Threatening Ischemia. N Engl J Med. 2018; 379(2):171-180. DOI: 10.1056/NEJMcp1709326. View

12.

Norgren L, Hiatt W, Dormandy J, Nehler M, Harris K, Fowkes F . Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II). J Vasc Surg. 2007; 45 Suppl S:S5-67. DOI: 10.1016/j.jvs.2006.12.037. View

13.

Rocha-Singh K, Zeller T, Jaff M . Peripheral arterial calcification: prevalence, mechanism, detection, and clinical implications. Catheter Cardiovasc Interv. 2014; 83(6):E212-20. PMC: 4262070. DOI: 10.1002/ccd.25387. View

14.

Soga Y, Iida O, Hirano K, Suzuki K, Tosaka A, Yokoi H . Utility of new classification based on clinical and lesional factors after self-expandable nitinol stenting in the superficial femoral artery. J Vasc Surg. 2011; 54(4):1058-66. DOI: 10.1016/j.jvs.2011.03.286. View

15.

Kawarada O, Fujihara M, Higashimori A, Yokoi Y, Honda Y, Fitzgerald P . Predictors of adverse clinical outcomes after successful infrapopliteal intervention. Catheter Cardiovasc Interv. 2012; 80(5):861-71. DOI: 10.1002/ccd.24370. View

16.

Fujihara M, Takahara M, Sasaki S, Nanto K, Utsunomiya M, Iida O . Angiographic Dissection Patterns and Patency Outcomes After Balloon Angioplasty for Superficial Femoral Artery Disease. J Endovasc Ther. 2017; 24(3):367-375. DOI: 10.1177/1526602817698634. View

17.

Shirai S, Hirano K, Mori S, Makino K, Honda Y, Tsutsumi M . Frequency, predictors, and effect of the slow-flow phenomenon after drug-coated balloon angioplasty for femoropopliteal lesions. Heart Vessels. 2021; 36(12):1818-1824. DOI: 10.1007/s00380-021-01871-6. View

18.

Kloner R, GANOTE C, Jennings R . The "no-reflow" phenomenon after temporary coronary occlusion in the dog. J Clin Invest. 1974; 54(6):1496-508. PMC: 301706. DOI: 10.1172/JCI107898. View

19.

Ito H, Tomooka T, Sakai N, Yu H, Higashino Y, Fujii K . Lack of myocardial perfusion immediately after successful thrombolysis. A predictor of poor recovery of left ventricular function in anterior myocardial infarction. Circulation. 1992; 85(5):1699-705. DOI: 10.1161/01.cir.85.5.1699. View

20.

Wang X, Nie S . The coronary slow flow phenomenon: characteristics, mechanisms and implications. Cardiovasc Diagn Ther. 2013; 1(1):37-43. PMC: 3839135. DOI: 10.3978/j.issn.2223-3652.2011.10.01. View